Skip to main content
Triple Negative Breast Cancer Discovered A New Drug Target

Triple negative breast cancer: a new drug target discovered

Thanks to their joint action, the combination of a new inhibitor molecule and a chemotherapy drug suppresses the growth of triple-negative breast cancer cells, one of the most aggressive breast cancers and one that responds the least to treatment.

Treatment of patients with triple negative breast cancer remains challenging due to the absence of well-defined molecular targets and the highly invasive nature of cancer cells.

Research led by Dr. Suresh Alahari, professor of biochemistry at LSU Health New Orleans Graduate Schools of Medicine and Studies, has reported that a combination of a new inhibitor molecule and an FDA-approved chemotherapy drug suppresses growth of triple negative breast cancer cells.

In the words of Dr. Alahari, the discovery "will be of great help to patients."

New drug discovery will be of great help to patients with triple-negative breast cancer."

Triple negative breast cancer is more common in young women and accounts for 15-20% of breast cancers. It is called triple negative because these tumors lack estrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2). »Because cancer cells do not have these proteins (estrogen and progesterone receptors and human epidermal growth factor receptor 2 of human epidermal growth), hormone therapy and drugs that target HER2 are not helpful," said Dr.

Prevention and early diagnosis of breast cancer

Metastatic triple-negative breast cancer mainly affects young women, an age group that is generally not included in breast cancer screening programmes.

In cases where cancer is detected, diagnosed and appropriately treated in its earliest stages, patients have a much higher survival rate than if the cancer is detected in later stages, when the cancer has spread or does not respond to treatment. .

The age of inclusion in the Breast Cancer Early Detection Program depends on each autonomous community, but in most cases only women who are in the age group considered to be at highest risk (between 50 and 69 years) can participate biannually.

Thanks to the mammography tumors can be visualized before they have invaded breast tissue, distant organs, or lymph nodes.

In this way, breast cancer can be identified at its earliest stage (up to 2 years before it becomes palpable) and an early diagnosis can be achieved that, with good treatment, can save lives.

En Women's CD Gynecological Clinic We recommend our patients to start having an annual mammogram together with the gynecological review from the 40 years.

And if there is a high risk of cancer due to a family history of breast or ovarian cancer, we recommend that mammography begin at age 30.

Women's, by your side

If you need more information or want to make a question, do not hesitate to contact us:

Whatsapp: 34 934 160 606

Email: info@womens.es

Make an appointment with our team

    I agree with the Privacy Policy

    This entry has 0 comments

    Leave your comment

    Your email address will not be published. Required fields are marked with *

    This site uses cookies for you to have the best user experience. If you continue to browse you are giving your consent to the acceptance of the aforementioned cookies and acceptance of our Cookies policy, Click the link for more information.plugin cookies

    ACCEPT
    Notice of cookies
    ASK FOR A DATE